Newer antidepressants

Review of efficacy and safety of escitalopram and duloxetine

Robert M A Hirschfeld, Lana A. Vornik

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Background: Two antidepressants with different mechanisms of action, escitalopram and duloxetine, have recently been developed for the treatment of major depressive disorder. This article reviews the available controlled data on these agents with regard to efficacy, safety, and tolerability. Method: We identified four 8-week, double-blind, placebo-controlled studies of escitalopram in the acute treatment of major depression. Three of the studies involved an active comparator, citalopram. We identified 6 placebo-controlled studies of duloxetine in major depressive disorder. Two of the studies included fluoxetine as an active comparator, and 2 included paroxetine as an active comparator. Results: A review of the data from the controlled studies supports the efficacy of both escitalopram and duloxetine in the treatment of patients with major depression. Three of the 4 escitalopram studies were positive, and 1 was a failed study. Four of the 6 duloxetine studies were positive. Both escitalopram and duloxetine performed better than at least 1 selective serotonin reuptake inhibitor comparator. The safety and tolerability profiles of both drugs are quite benign. The reported incidence of treatmentemergent adverse events was somewhat lower with escitalopram than with duloxetine, with the possible exception of sexual dysfunction. Discontinuations due to adverse events were lower for escitalopram than for duloxetine, although rates were comparable with higher doses of escitalopram (20 mg/day). Conclusion: Both escitalopram and duloxetine are useful in the treatment of major depressive disorder.

Original languageEnglish (US)
Pages (from-to)46-52
Number of pages7
JournalJournal of Clinical Psychiatry
Volume65
Issue numberSUPPL. 4
StatePublished - 2004

Fingerprint

Citalopram
Antidepressive Agents
Safety
Major Depressive Disorder
Placebos
Duloxetine Hydrochloride
Depression
Paroxetine
Fluoxetine
Serotonin Uptake Inhibitors
Therapeutics

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Newer antidepressants : Review of efficacy and safety of escitalopram and duloxetine. / Hirschfeld, Robert M A; Vornik, Lana A.

In: Journal of Clinical Psychiatry, Vol. 65, No. SUPPL. 4, 2004, p. 46-52.

Research output: Contribution to journalArticle

Hirschfeld, Robert M A ; Vornik, Lana A. / Newer antidepressants : Review of efficacy and safety of escitalopram and duloxetine. In: Journal of Clinical Psychiatry. 2004 ; Vol. 65, No. SUPPL. 4. pp. 46-52.
@article{9d7ebae63309433e90424d3a86998f36,
title = "Newer antidepressants: Review of efficacy and safety of escitalopram and duloxetine",
abstract = "Background: Two antidepressants with different mechanisms of action, escitalopram and duloxetine, have recently been developed for the treatment of major depressive disorder. This article reviews the available controlled data on these agents with regard to efficacy, safety, and tolerability. Method: We identified four 8-week, double-blind, placebo-controlled studies of escitalopram in the acute treatment of major depression. Three of the studies involved an active comparator, citalopram. We identified 6 placebo-controlled studies of duloxetine in major depressive disorder. Two of the studies included fluoxetine as an active comparator, and 2 included paroxetine as an active comparator. Results: A review of the data from the controlled studies supports the efficacy of both escitalopram and duloxetine in the treatment of patients with major depression. Three of the 4 escitalopram studies were positive, and 1 was a failed study. Four of the 6 duloxetine studies were positive. Both escitalopram and duloxetine performed better than at least 1 selective serotonin reuptake inhibitor comparator. The safety and tolerability profiles of both drugs are quite benign. The reported incidence of treatmentemergent adverse events was somewhat lower with escitalopram than with duloxetine, with the possible exception of sexual dysfunction. Discontinuations due to adverse events were lower for escitalopram than for duloxetine, although rates were comparable with higher doses of escitalopram (20 mg/day). Conclusion: Both escitalopram and duloxetine are useful in the treatment of major depressive disorder.",
author = "Hirschfeld, {Robert M A} and Vornik, {Lana A.}",
year = "2004",
language = "English (US)",
volume = "65",
pages = "46--52",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "SUPPL. 4",

}

TY - JOUR

T1 - Newer antidepressants

T2 - Review of efficacy and safety of escitalopram and duloxetine

AU - Hirschfeld, Robert M A

AU - Vornik, Lana A.

PY - 2004

Y1 - 2004

N2 - Background: Two antidepressants with different mechanisms of action, escitalopram and duloxetine, have recently been developed for the treatment of major depressive disorder. This article reviews the available controlled data on these agents with regard to efficacy, safety, and tolerability. Method: We identified four 8-week, double-blind, placebo-controlled studies of escitalopram in the acute treatment of major depression. Three of the studies involved an active comparator, citalopram. We identified 6 placebo-controlled studies of duloxetine in major depressive disorder. Two of the studies included fluoxetine as an active comparator, and 2 included paroxetine as an active comparator. Results: A review of the data from the controlled studies supports the efficacy of both escitalopram and duloxetine in the treatment of patients with major depression. Three of the 4 escitalopram studies were positive, and 1 was a failed study. Four of the 6 duloxetine studies were positive. Both escitalopram and duloxetine performed better than at least 1 selective serotonin reuptake inhibitor comparator. The safety and tolerability profiles of both drugs are quite benign. The reported incidence of treatmentemergent adverse events was somewhat lower with escitalopram than with duloxetine, with the possible exception of sexual dysfunction. Discontinuations due to adverse events were lower for escitalopram than for duloxetine, although rates were comparable with higher doses of escitalopram (20 mg/day). Conclusion: Both escitalopram and duloxetine are useful in the treatment of major depressive disorder.

AB - Background: Two antidepressants with different mechanisms of action, escitalopram and duloxetine, have recently been developed for the treatment of major depressive disorder. This article reviews the available controlled data on these agents with regard to efficacy, safety, and tolerability. Method: We identified four 8-week, double-blind, placebo-controlled studies of escitalopram in the acute treatment of major depression. Three of the studies involved an active comparator, citalopram. We identified 6 placebo-controlled studies of duloxetine in major depressive disorder. Two of the studies included fluoxetine as an active comparator, and 2 included paroxetine as an active comparator. Results: A review of the data from the controlled studies supports the efficacy of both escitalopram and duloxetine in the treatment of patients with major depression. Three of the 4 escitalopram studies were positive, and 1 was a failed study. Four of the 6 duloxetine studies were positive. Both escitalopram and duloxetine performed better than at least 1 selective serotonin reuptake inhibitor comparator. The safety and tolerability profiles of both drugs are quite benign. The reported incidence of treatmentemergent adverse events was somewhat lower with escitalopram than with duloxetine, with the possible exception of sexual dysfunction. Discontinuations due to adverse events were lower for escitalopram than for duloxetine, although rates were comparable with higher doses of escitalopram (20 mg/day). Conclusion: Both escitalopram and duloxetine are useful in the treatment of major depressive disorder.

UR - http://www.scopus.com/inward/record.url?scp=2142643100&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2142643100&partnerID=8YFLogxK

M3 - Article

VL - 65

SP - 46

EP - 52

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - SUPPL. 4

ER -